Pegcetacoplan vs Avacincaptad Pegol in Geographic Atrophy: An Anchored Matching-Adjusted Indirect Comparison of Three Phase 3 Trials

Access Resources

Long-Term Efficacy and Safety of Pegcetacoplan Over 36 Months: Results From 12 Months of the GALE Open-Label Extension Study

Access Resources

Pegcetacoplan Delays Time to Loss of Central Macular Sensitivity: A Microperimetry Analysis of the Phase 3 OAKS Study

Access Resources

The Photoreceptor/Retinal Pigment Epithelium Integrity Loss (PR/RPE Ratio) in Geographic Atrophy Secondary to AMD Is a Significant Predictor for Disease Activity and Therapeutic Response

Access Resources